Search Results for "Dcis Recurrence After Mastectomy"

08:27 EST 18th December 2014 | BioPortfolio

Original Source: Analyzing the Risk of Recurrence after Mastectomy for DCIS: A New Use for the USC/Van Nuys Prognostic Index.

BACKGROUND: Patients with ductal carcinoma in situ (DCIS) who are treated with mastectomy seldom recur locally or with metastatic disease. When patients with DCIS recur with invasive cancer, they are upstaged and their lives are threatened. We questioned whether histopathologic data could be used to predict these infrequent events. METHODS: We reviewed a prospective database of 1,472 patients with pure DCIS. All patients were scored from 4 to 12 using the USC Van Nuys Prognostic Index, an algorithm based on...

Matching Channels

Tumor recurrence

Oncotrace

For optimal treatment in cancerology, clinicians need specific, precise, sensitive methods to quantify treatment response, monitor residual disease and detect early recurrence in patients. Residual ...

WolffParkinsonWhite WPW syndrome

Wolff–Parkinson–White syndrome (WPW) is a syndrome of pre-excitation of ventricles of the heart due to an accessory pathway known as the bundle of Kent. This accessory pathway is an abno...

UroGenRA - Genitourinary cancer array

UroGenRA is a CGI custom-designed oligonucleotide array for implementation within a clinical laboratory as an array CGH-based diagnostic/prognostic tool for kidney, prostate, and bladder cancers. It...

Tumor markers

Tumor markers are substances produced by tumor cells or by other cells of the body in response to cancer or certain benign (noncancerous) conditions. These substances can be found in the blood, in t...

Matching News

20 Years Later, Radiation Protects Against DCIS Recurrence

Rates of recurrence of ductal carcinoma in situ (DCIS) after breast-conserving surgery (BCS) remain lower 20 years after radiotherapy, according to results from the SweDCIS Trial. Reuters Health Inf...

Multigene test can predict risk of disease recurrence for women with ductal carcinoma in situ

In a press conference at SABCS 2014, Prof Rakovitch discusses the use of a multigene test called Oncotype DX DCIS Score (DCIS Score) as a predictor of risk of disease recurrence for patients with d...

Recurrence risk could be predicted by a multigene test in ductal carcinoma breast cancer

Prof Rakovitch talks to ecancertv at SABCS 2014 about the use of a multigene test called Oncotype DX DCIS Score (DCIS Score) which seeks to predict of risk of disease recurrence for patients with duct...

DCIS Test Identifies Patients With Low Recurrence Risk

A new Oncotype test identifies patients with ductal carcinoma in situ (DCIS) who are at low risk for recurrence and for the development of invasive breast cancer. Medscape Medical News

Top stories in health and medicine, December 17, 2014

From MedPage Today: Gene Test Has Promise for Nailing DCIS Recurrence Risk. A multigene panel predicted recurrence risk in ductal carcinoma in situ (DCIS), according to a population-based study. Docs...

SABCS 2014: Multigene test can predict risk of disease recurrence for women with ductal carcinoma in situ

A multigene test called Oncotype DX DCIS Score (DCIS Score) was validated as a predictor of risk of disease recurrence among women treated with breast-conserving surgery alone for ductal carcinoma in ...

Oncotype DX® DCIS Score™ Represents Breakthrough in Personalizing Treatment of Pre-Invasive Breast Cancer

SAN ANTONIO, Dec. 12, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive results from the second large clinical validation study of Oncotype DX® in patients with a ...

Comment: Multigene test can predict risk of disease recurrence for women with ductal carcinoma in situ

Prof Osborne provides ecancertv with his expert opition on data presented at SABCS 2014 by Prof Rakovitch about the use of a multigene test called Oncotype DX DCIS Score (DCIS Score) as a predicto...

Matching PubMed Articles

A Comparison of Tumor Biology in Primary Ductal Carcinoma In Situ Recurring as Invasive Carcinoma versus a New In Situ.

Introduction. About half of all new ipsilateral events after a primary ductal carcinoma in situ (DCIS) are invasive carcinoma. We studied tumor markers in the primary DCIS in relation to type of event...

Impact of Breast Reconstruction on the Decision to Undergo Contralateral Prophylactic Mastectomy.

In the last decade, there has been increasing use of contralateral prophylactic mastectomy (CPM) in patients with unilateral breast cancer and ductal carcinoma-in-situ (DCIS) undergoing mastectomy. Al...

The current clinical value of the DCIS Score.

The management of ductal carcinoma in situ (DCIS) can be controversial. Widespread adoption of mammographic screening has made DCIS a more frequent diagnosis, and increasingly smaller, lower-grade les...

Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis.

The main goal of treating ductal carcinoma in situ (dcis) is to prevent the development of invasive breast cancer. Most women are treated with breast-conserving surgery (bcs) and radiotherapy. Age at ...

Smoking and breast cancer recurrence after breast conservation therapy.

Background. Prior studies have shown earlier recurrence and decreased survival in patients with head and neck cancer who smoked while undergoing radiation therapy. The purpose of the current study was...

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement